19:53 , May 12, 2017 |  BC Week In Review  |  Financial News

Dermtreat raises $17.7M in series A

On May 8, mucosal disease company Dermtreat ApS (Copenhagen, Denmark) raised $17.7 million in a series A led by Sofinnova Ventures. Also participating were Novo Seeds, Lundbeckfonden Emerge and undisclosed existing shareholders. Dermtreat’s existing investors...
23:05 , May 8, 2017 |  BC Extra  |  Financial News

Dermtreat's series A round brings in $17.7M

Mucosal disease company Dermtreat ApS (Copenhagen, Denmark) raised $17.7 million in a series A round led by Sofinnova Ventures. Also participating were Novo Seeds, Lundbeckfonden Emerge and existing shareholders including Welfare Tech Invest. Dermtreat CEO Jens...
16:32 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Natesto regulatory update

Hyundai submitted an NDA to South Korea’s Ministry of Food and Drug Safety (MFDS) for Natesto to treat low testosterone. Hyundai has exclusive, South Korean rights to the bioadhesive intranasal gel formulation of testosterone from...
07:00 , May 9, 2016 |  BC Week In Review  |  Company News

Acerus Pharmaceuticals, Aytu deal

Acerus (formerly Trimel Pharmaceuticals Corp.) granted Aytu exclusive, U.S. marketing rights to testosterone replacement therapy Natesto testosterone nasal gel, effective June 30. Acerus will receive an $8 million upfront payment and is eligible...
07:00 , May 2, 2016 |  BC Week In Review  |  Financial News

Acerus Pharmaceuticals completes private placement

Acerus Pharmaceuticals Corp. (TSX:ASP), Mississauga, Ontario   Business: Drug delivery, Endocrine/Metabolic, Inflammation   Date completed: 2016-04-27   Type: Private placement   Raised: C$2.5 million ($2 million)   Shares: 12.2 million   Price: C$0.21   Shares after offering: 213.1 million   Investor: Aytu...
01:25 , Jul 14, 2015 |  BC Extra  |  Company News

Management tracks

Antibody company AnaptysBio Inc. (San Diego, Calif.) hired Robert Hoffman as CFO. Hoffman was SVP of finance and CFO at Arena Pharmaceuticals Inc. (NASDAQ:ARNA). Oncology play Tesaro Inc. (NASDAQ:TSRO) named Grant Bogle SVP and chief...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Endo sales and marketing update

Endo launched testosterone replacement therapy Natesto testosterone nasal gel in the U.S. Natesto is a bioadhesive intranasal gel formulation of testosterone delivered by metered-dose pump. One pump delivers 5.5 mg of testosterone. The recommended...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Natesto regulatory update

Trimel submitted an NDS to Health Canada for Natesto testosterone nasal gel as replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone. The bioadhesive intranasal gel formulation of testosterone...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Trimel Pharmaceuticals, Endo deal

Trimel granted Endo exclusive rights to commercialize Natesto in the U.S. and Mexico. FDA approved the bioadhesive intranasal gel formulation of testosterone in May to treat testosterone deficiency. Endo plans to launch it in...
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co.'s 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes it...